Who are Benzidamine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Inomax, Topical Nitroglycerine, Inhaled Nitric Oxide (iNO) use, nadolol + ISMN, Nitroglycerin patch, Nitroglycerin (NTG).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/benzydamine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Benzidamine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Benzidamine (BENZYDAMINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: benzydamine. Area: Pain.

phase 3 benzydamine Soluble guanylate cyclase Pain Small molecule Live · refreshed every 30 min

Target snapshot

Benzidamine (BENZYDAMINE). Benzidamine works by activating soluble guanylate cyclase, an enzyme that produces cyclic guanosine monophosphate (cGMP), leading to pain relief.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Benzidamine TARGET	BENZYDAMINE		phase 3	benzydamine	Soluble guanylate cyclase
Inomax	NITRIC OXIDE	Vero Biotech Inc	marketed	Standardized Chemical Allergen [EPC]	Soluble guanylate cyclase	1999-01-01
Topical Nitroglycerine	Topical Nitroglycerine	Aultman Health Foundation	marketed	Nitrate vasodilator	Soluble guanylate cyclase (via nitric oxide)
Inhaled Nitric Oxide (iNO) use	Inhaled Nitric Oxide (iNO) use	The University of Texas Health Science Center, Houston	marketed	Inhaled vasodilator	Soluble guanylate cyclase
nadolol + ISMN	nadolol + ISMN	E-DA Hospital	marketed	Beta-blocker + Nitrate combination	Beta-adrenergic receptors (nadolol); soluble guanylate cyclase (ISMN)
Nitroglycerin patch	Nitroglycerin patch	GF Strong Rehabilitation Centre	marketed	Nitrate vasodilator	Soluble guanylate cyclase (via nitric oxide)
Nitroglycerin (NTG)	Nitroglycerin (NTG)	Bristol-Myers Squibb	marketed	Nitrate vasodilator	Soluble guanylate cyclase (via nitric oxide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (benzydamine class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Benzidamine — Competitive Intelligence Brief. https://druglandscape.com/ci/benzydamine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing